Founded in 2016 by John Luk, Arbele is based in Redmond, Washington and aims to excel patient healthcare through breakthrough immunotherapy. The company's expertise lies in antibody-based therapeutic platforms, including CAR-T and Bi-specific antibody technology, as well as CRISPR genome editing. Arbele collaborates with leading academic institutes, biotechs, and medical centers to advance its drug candidates through clinical stages. With a founding team that has over 30 years of experience in multinational drug companies, Arbele is focused on accelerating the development of immunotherapy technology to treat prevalent cancers in the Greater China, Asia-Pacific region, and the United States.